Senzime receives research grants from the EU's Horizon 2020

Uppsala, May 13, 2015. In intense competition with other companies Senzime receives EUR 50 000 in funding from the EU's "Horizon 2020" to a feasibility study of a body and near-patient method for measuring glucose. The feasibility study is expected to be completed during the second half of 2015 and with good results; this can result in significant funding for the company's future clinical development of the concept. Furthermore, the recently acquired MD Biomedical received EUR 50 000 in appropriations in order to ensure how organs in newly operated patients works, an area where there are significant medical needs.

The goal of Senzime’s study is to show a body and near-patient, specific, and accurate glucose meters that can be installed in intensive care, which provides a solution to the current unmet clinical needs. The feasibility study is expected to take six months, and with good results there are opportunities to apply for additional EU funding for the continued clinical documentation.

"Blood glucose measurement in health care is often linked to diabetes care. Although this is a very broad sector of health care where blood glucose measurement is of interest, it is not the only one. Research in recent years has shown that if you can maintain normal blood glucose level during and after operation of critically ill patients in intensive care units, whether they are diabetic or not, reduced morbidity and mortality among these patients. We see Horizon 2020 grant as further confirmation that the measurement of glucose in the blood is important and that Senzime is a leading player in the field, "says Lena Söderström, CEO of Senzime AB.

Further, annually thousands of complex surgeries to improve and save the lives of patients are conducted, but it has so far been difficult to measure how the operated organs function after surgery. MD Biomedical has developed a method that can measure this and it will now be proven in a clinical study.

"We have managed to convey what we can and will do in strong international competition, and it's incredibly encouraging. Now we will build on our network of partners who want to test and verify our method through clinical trials, says Pernilla Abrahamsson, product and business development manager MD Biomedical /Senzime.

For further information, please contact:

Lena Söderström, CEO Senzime AB
Tel: +46-708-16 39 12, e-mail:

About Senzime

Senzime develops and sells analytical instruments and related disposable products that enable automated, continuous monitoring of vital substances including glucose (sugar), in biological fluids. Many modern medicines are produced in living cells that are nourished in a glucose solution. In order to ensure maximum productivity in manufacturing, glucose levels should be measured continuously. Continuous glucose monitoring can also be used by healthcare providers, to improve outcomes of complex surgical procedures. Other areas where online monitoring can be useful are in research, dialysis care and sports. The company's share is listed on Aktietorget since 2008.


About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime.


Documents & Links